Hectorol pre-dialysis indication
This article was originally published in Pharmaceutical Approvals Monthly
Bone Care International expands use of its secondary hyperparathyroidism agent Hectorol to include pre-dialysis patients with moderate to severe chronic kidney disease with an April 23 approval; doxercalciferol is already approved for use in dialysis patients. The vitamin D hormone had been "approvable" for the pre-dialysis indication since October 2002 (1Pharmaceutical Approvals Monthly Nov. 1, 2002, In Brief). FDA is asking for a Phase IV trial "to address recommendations made in the National Kidney Foundation K/DOQI guidelines regarding safety and efficacy of doxercalciferol in lowering elevated iPTH to within accepted ranges in 'vitamin D sufficient' patients with Stages 3 and 4 [CKD]." A two-year carcinogenicity study also is requested...
You may also be interested in...
FDA-crafted labeling for Amgen’s Sensipar anticipates off-label use of the secondary hyperparathyroidism therapy in pre-dialysis patients, review documents for the NDA show.
Bone Care International is preparing a written response to FDA's Oct. 25 "approvable" letter for Hectorol (doxercalciferol) capsules. Approval depends on "satisfactory response" to questions about the firm's clinical trial and agreement on labeling. The sNDA covers secondary hyperparathyroidism in chronic kidney disease patients prior to dialysis. Hectorol is currently approved for chronic renal dialysis patients. Bone Care says it does not intend to seek the indication for its injectable Hectorol formulatio
Lack of official explanation about how the exchange of critical information will progress pending the launch of the EU’s medical device database, Eudamed3, has left many confused. New guidance lights the way forward.